Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Strides-Pharma"

54 News Found

Strides Pharma Science to invest in AMP-6, AMP-8
News | January 03, 2024

Strides Pharma Science to invest in AMP-6, AMP-8

AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka


Strides Pharma Science extends guarantee to Trinity Pharma Proprietary’s borrowing
News | December 22, 2023

Strides Pharma Science extends guarantee to Trinity Pharma Proprietary’s borrowing

Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore


Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma
News | September 08, 2023

Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma

Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.


Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
News | January 21, 2023

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.


Strides Pharma Global receives AUD 94 mn for sale of Australia's operations
News | December 23, 2022

Strides Pharma Global receives AUD 94 mn for sale of Australia's operations

The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument


Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
News | May 26, 2022

Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr

The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.


Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool
News | January 20, 2022

Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool

They will commercialize molnupiravir in the international markets


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US


Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
News | May 27, 2021

Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21

Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21